Analysis of Zuoli Pharmaceutical's Acquisition of the Trace Element Injection Asset Group from Tibet Future Biology

Based on existing information, I conduct a comprehensive analysis of Zuoli Pharmaceutical’s this acquisition:

According to search results, Zuoli Pharmaceutical (300181.SZ) plans to acquire the

of Tibet Future Biology Co., Ltd. for approximately [1][2]. This is a major strategic merger and acquisition transaction.

Zuoli Pharmaceutical is a listed company focusing on biomedicine, with a current market capitalization of approximately USD 11.26 billion [0]. The company’s core products and business characteristics are as follows:

• Wuling Capsule
  - Core product, used for symptoms such as insomnia, forgetfulness, palpitations, irritability, and fatigue caused by disharmony between the heart and kidneys
• Drugs in the neurological field
• Oral preparations such as capsules, tablets, granules, dispensing granules, and Chinese herbal pieces [3]

• Indications focus on
  middle-aged and elderly groups
  (symptoms like insomnia, forgetfulness)
• Product form is mainly
  oral preparations
• Mainly covers the
  neurological disease
  field [3]

• Covers all age groups, including children, pregnant women, and the elderly
• Clinical applications: Nutritional supplementation, adjuvant treatment of diseases
• Formulation advantages: Injectable formulation, fast absorption, high bioavailability

Dimension	Before Acquisition	After Acquisition	Synergy Effect
Age Coverage	Mainly middle-aged and elderly groups	Expanded to all age groups	✓ Significant improvement
Formulation Complementation	Mainly oral preparations	Added injectable formulations	✓ Product category expansion
Therapeutic Field	Mainly neurological system	Extended to nutritional supplementation	✓ Product category expansion
Channel Expansion	Retail + hospitals	Strengthened hospital channels	✓ Dual-wheel drive

1. Full Age Coverage Complementation
   : Successfully achieved product layout covering all age groups from a single focus on middle-aged and elderly groups
2. Formulation Complementation
   : Filled the gap in injectable formulations and improved product form combination
3. Product Category Expansion
   : Extended from the neurological system to the nutritional supplementation field, reducing dependence on a single field
4. Channel Synergy
   : Injectables are mainly in hospital channels, which can complement the existing retail channels

1. Large Investment Scale
   : The RMB 3.56 billion poses challenges to the company’s capital and integration capabilities
2. Capacity Construction
   : Need to establish injectable production lines and quality control systems
3. Market Competition
   : The trace element injection market is highly competitive
4. Integration Risks
   : Challenges such as asset group integration and management team integration

This acquisition

, which is verified from the following aspects:

1. Product Dimension
   : Trace element injections are suitable for all age groups, directly filling the product gap for children, pregnant women, and other groups
2. Strategic Alignment
   : Highly aligned with the company’s “AI Empowerment · All the Way to C” strategy and layout in the big health track
3. Market Opportunity
   : The full-age nutritional supplementation market has broad space and is in line with the consumption upgrade trend

However, it should be noted that the RMB 3.56 billion investment needs to generate corresponding performance returns, and the company’s integration effect and performance in the next 2-3 years will be the key indicators to verify the success of this acquisition.

---

[1] Eastmoney.com - Images related to Zuoli Pharmaceutical’s acquisition announcement (https://gbres.dfcfw.com/Files/iimage/20251214/EC1972C39428118D7CF615361D694222_w700h467.jpg)

[2] Image Bus - Announcement of Zhejiang Zuoli Pharmaceutical Co., Ltd. on Asset Acquisition and Connected Transactions (https://img1.utuku.imgcdc.com/650x0/finance/20251216/ab401deb-c429-43fc-bf53-860c0c5119a5.png)

[3] Zuoli Pharmaceutical Official Website - Product Center (https://www.zuoli.com/product_detail.aspx?k1=3&k2=23&id=129)

[0] Jinling API Data - Zuoli Pharmaceutical Company Overview and Stock Price Data